JP2013541502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541502A5 JP2013541502A5 JP2013523342A JP2013523342A JP2013541502A5 JP 2013541502 A5 JP2013541502 A5 JP 2013541502A5 JP 2013523342 A JP2013523342 A JP 2013523342A JP 2013523342 A JP2013523342 A JP 2013523342A JP 2013541502 A5 JP2013541502 A5 JP 2013541502A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- dione
- independently
- composition according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 208000012268 mitochondrial disease Diseases 0.000 claims description 10
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 6
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims description 5
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 4
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 4
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 230000007950 acidosis Effects 0.000 claims description 2
- 208000026545 acidosis disease Diseases 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- QDUAOKYKHMKPTA-UHFFFAOYSA-N 2-methyl-3-nonylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCC)=C(C)C(=O)C2=C1 QDUAOKYKHMKPTA-UHFFFAOYSA-N 0.000 claims 2
- -1 R 3c is Chemical group 0.000 claims 2
- LGFDNUSAWCHVJN-UHFFFAOYSA-N 2,3-dimethyl-1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C(C)=C(C)C(=O)C2=C1 LGFDNUSAWCHVJN-UHFFFAOYSA-N 0.000 claims 1
- ZYZWUEIPVNFQQC-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)(O)CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 ZYZWUEIPVNFQQC-UHFFFAOYSA-N 0.000 claims 1
- PFCSRGNFXBREEI-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)(O)CCC=C(C)C)=CC(=O)C2=C1 PFCSRGNFXBREEI-UHFFFAOYSA-N 0.000 claims 1
- BXRGMKVTCTWHRD-UHFFFAOYSA-N 2-butyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCC)=C(C)C(=O)C2=C1 BXRGMKVTCTWHRD-UHFFFAOYSA-N 0.000 claims 1
- JZCYOZPRLAGWSS-UHFFFAOYSA-N 2-decyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCC)=C(C)C(=O)C2=C1 JZCYOZPRLAGWSS-UHFFFAOYSA-N 0.000 claims 1
- DTGKPFYIFROSOP-UHFFFAOYSA-N 2-heptadecyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 DTGKPFYIFROSOP-UHFFFAOYSA-N 0.000 claims 1
- YAKBITAXCOOTRG-UHFFFAOYSA-N 2-heptyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCC)=C(C)C(=O)C2=C1 YAKBITAXCOOTRG-UHFFFAOYSA-N 0.000 claims 1
- DIIHNBLSXDGYNT-UHFFFAOYSA-N 2-hexyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCC)=C(C)C(=O)C2=C1 DIIHNBLSXDGYNT-UHFFFAOYSA-N 0.000 claims 1
- FATIXBDICXNSAQ-UHFFFAOYSA-N 2-icosyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 FATIXBDICXNSAQ-UHFFFAOYSA-N 0.000 claims 1
- MOYPRYFRIDZWHC-UHFFFAOYSA-N 2-methyl-3-(3,7,11-trimethyldodecyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MOYPRYFRIDZWHC-UHFFFAOYSA-N 0.000 claims 1
- JCSUQQOAHQRPBF-UHFFFAOYSA-N 2-methyl-3-(3-methylbutyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)C)=C(C)C(=O)C2=C1 JCSUQQOAHQRPBF-UHFFFAOYSA-N 0.000 claims 1
- SUVLFHKXBHCAKS-UHFFFAOYSA-N 2-methyl-3-nonadecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 SUVLFHKXBHCAKS-UHFFFAOYSA-N 0.000 claims 1
- ANJYWYTXJPIQLS-UHFFFAOYSA-N 2-methyl-3-octylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCC)=C(C)C(=O)C2=C1 ANJYWYTXJPIQLS-UHFFFAOYSA-N 0.000 claims 1
- ONKIICPFVVQPJA-UHFFFAOYSA-N 2-methyl-3-pentadecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 ONKIICPFVVQPJA-UHFFFAOYSA-N 0.000 claims 1
- XTMWDFCOWHNAPA-UHFFFAOYSA-N 2-methyl-3-pentylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCC)=C(C)C(=O)C2=C1 XTMWDFCOWHNAPA-UHFFFAOYSA-N 0.000 claims 1
- GIQISUKKXZTPJV-UHFFFAOYSA-N 2-methyl-3-propylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC)=C(C)C(=O)C2=C1 GIQISUKKXZTPJV-UHFFFAOYSA-N 0.000 claims 1
- PUURYLDVOHSJSZ-UHFFFAOYSA-N 2-methyl-3-tetradecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 PUURYLDVOHSJSZ-UHFFFAOYSA-N 0.000 claims 1
- MVFUHAWRIKCIAB-UHFFFAOYSA-N 2-methyl-3-tridecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCC)=C(C)C(=O)C2=C1 MVFUHAWRIKCIAB-UHFFFAOYSA-N 0.000 claims 1
- 229930192627 Naphthoquinone Natural products 0.000 claims 1
- 150000002791 naphthoquinones Chemical class 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 description 6
- 102000018832 Cytochromes Human genes 0.000 description 4
- 108010052832 Cytochromes Proteins 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 0 C*C(C(c1cc(I)c(*=C)cc11)=N)=C(**(*)[I-])C1=Cl Chemical compound C*C(C(c1cc(I)c(*=C)cc11)=N)=C(**(*)[I-])C1=Cl 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40104410P | 2010-08-06 | 2010-08-06 | |
| US61/401,044 | 2010-08-06 | ||
| PCT/US2011/046630 WO2012019029A2 (en) | 2010-08-06 | 2011-08-04 | Treatment of mitochondrial diseases with naphthoquinones |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000265A Division JP2016041772A (ja) | 2010-08-06 | 2016-01-04 | ナフトキノンによるミトコンドリア病の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541502A JP2013541502A (ja) | 2013-11-14 |
| JP2013541502A5 true JP2013541502A5 (https=) | 2015-04-02 |
| JP6045494B2 JP6045494B2 (ja) | 2016-12-14 |
Family
ID=45560075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523342A Expired - Fee Related JP6045494B2 (ja) | 2010-08-06 | 2011-08-04 | ナフトキノンによるミトコンドリア病の処置 |
| JP2016000265A Pending JP2016041772A (ja) | 2010-08-06 | 2016-01-04 | ナフトキノンによるミトコンドリア病の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000265A Pending JP2016041772A (ja) | 2010-08-06 | 2016-01-04 | ナフトキノンによるミトコンドリア病の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130345312A1 (https=) |
| EP (1) | EP2600857A4 (https=) |
| JP (2) | JP6045494B2 (https=) |
| AU (1) | AU2011285619B2 (https=) |
| BR (1) | BR112013002877A2 (https=) |
| CA (1) | CA2807507A1 (https=) |
| EA (1) | EA201300215A1 (https=) |
| MX (1) | MX2013001469A (https=) |
| SG (1) | SG187744A1 (https=) |
| WO (1) | WO2012019029A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| HUE033757T2 (en) | 2012-07-12 | 2017-12-28 | Khondrion Ip B V | Chromanyl derivatives for treating mitochondrial disease |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CN110339339A (zh) * | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA2936146A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| ES3033538T3 (en) | 2015-10-08 | 2025-08-05 | Khondrion Ip B V | Novel compounds for treating mitochondrial disease |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| KR102660473B1 (ko) | 2017-04-05 | 2024-04-24 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환의 신규 치료 |
| CN110582480B (zh) * | 2017-04-21 | 2023-11-10 | 塔斯马尼亚大学 | 治疗化合物和方法 |
| WO2020028222A1 (en) * | 2018-07-29 | 2020-02-06 | Musc Foundation For Research Development | Compounds for the treatment of neurological or mitochondrial diseases |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| CN113473977A (zh) | 2019-01-25 | 2021-10-01 | 巴塞罗那自治大学 | 用于治疗线粒体疾病用途的大麻二酚和/或其衍生物 |
| CN114746430B (zh) | 2019-10-04 | 2026-01-30 | 康德生物医疗有限公司 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
| US12037350B2 (en) | 2020-04-03 | 2024-07-16 | Stealth Biotherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia |
| IT202100006065A1 (it) * | 2021-03-15 | 2022-09-15 | Univ Degli Studi Padova | Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| JP2003226639A (ja) * | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用 |
| US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
| EP2471530B1 (en) * | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| US9278085B2 (en) * | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| KR20080047959A (ko) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물 |
| WO2009111576A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2344142B1 (en) * | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| US20110172312A1 (en) * | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EP2601168A4 (en) * | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
-
2011
- 2011-08-04 EA EA201300215A patent/EA201300215A1/ru unknown
- 2011-08-04 MX MX2013001469A patent/MX2013001469A/es unknown
- 2011-08-04 BR BR112013002877A patent/BR112013002877A2/pt not_active Application Discontinuation
- 2011-08-04 JP JP2013523342A patent/JP6045494B2/ja not_active Expired - Fee Related
- 2011-08-04 US US13/814,721 patent/US20130345312A1/en not_active Abandoned
- 2011-08-04 AU AU2011285619A patent/AU2011285619B2/en not_active Ceased
- 2011-08-04 WO PCT/US2011/046630 patent/WO2012019029A2/en not_active Ceased
- 2011-08-04 EP EP11815334.5A patent/EP2600857A4/en not_active Withdrawn
- 2011-08-04 SG SG2013009212A patent/SG187744A1/en unknown
- 2011-08-04 CA CA2807507A patent/CA2807507A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000265A patent/JP2016041772A/ja active Pending